

Cover Story
Guest Editorial
By John H. Stewart and Robert A. Winn
Advances in the field of tumor immunotherapy have given great hope for those treating cancer. We are in an era of unprecedented achievements, as evidenced by impressive clinical responses in patients treated with adoptive cell therapy and immune checkpoint inhibitors.
By Claire Dietz and Matthew Bin Han Ong
In Brief
Clinical Roundup


Drugs & Targets


NCI Trials


NCI Trials for May
The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month.
Trending Stories
- With five-year cancer survival at an all-time high, does this mean people are living longer?
- House passes three-year extension of ACA subsidies with bipartisan support
- When “safe and effective” is not “reasonable and necessary”
We can curb excessive drug dosing and improve the quality of cancer care - Gonzalez-Angulo Found Guilty In MD Anderson Poisoning Case
- The Mark Foundation names 2026 Emerging Leader Award recipients
- A radiation oncologist’s perspective: Why we need to accelerate early detection strategies for lung cancers















